FDA Lifts Stay on Repeal of FD&C Red No. 3 Regulations After Rejecting Micro‑Tracers' Objections
More From This Agency
- HHS Notices Prospective Exclusive Patent License for Mifepristone Analogs to Treat Hypercortisolism-Related Insulin Resistance September 2, 2026
- HRSA Seeks Public Comment on Proposed Faculty Loan Repayment Program Data Collection (OMB No. 0906-0082-Revision) August 21, 2026
- HHS Seeks 3‑Year Generic Clearance to Collect TEFCA Feedback August 17, 2026
- FDA Determines ANSAID (Flurbiprofen) Tablets Were Not Withdrawn for Safety or Effectiveness August 17, 2026
- NCI Offers License for CRISPR-Engineered MC38 B2m‑KO Murine Colon Cancer Cell Line August 16, 2026
Plain-English Summary
The FDA reviewed objections filed by Micro‑Tracers, Inc. regarding a petition to repeal regulations that permit the safe use of FD&C Red No. 3 in food, supplements, and ingested drugs. The agency concluded the objections did not raise material factual issues and therefore denied a public hearing. Consequently, the administrative stay on the repeal and delisting of the color‑additive rules has been lifted. The repeal will now become effective as originally intended.
Current Status
Final rule – the agency has issued a final decision and removed the stay, making the regulatory change effective.
What This Means
The FDA’s decision means that the proposed repeal of specific regulations governing the use of FD&C Red No. 3 will now proceed without further delay. By finding no material fact disputes, the agency has determined a hearing is unnecessary, so the administrative hold on the effective date is removed. Once the repeal takes effect, the existing safety standards for Red 3 in food, dietary supplements, and ingested drugs will no longer apply. Manufacturers will no longer need to comply with the prior specific safety requirements for this color additive. The change is administrative; it does not itself alter the underlying statutory authority to regulate color additives.
Who Is Affected
Food manufacturers, dietary‑supplement producers, and pharmaceutical companies that use FD&C Red No. 3 will be directly impacted, as they will no longer be bound by the repealed safety regulations. FDA oversight of color additive safety will shift, potentially requiring firms to rely on broader safety assessments. Consumers could encounter products with Red 3 that are not subject to the previously detailed safety conditions. The Health and Human Services Department, through the FDA, remains the primary regulator overseeing the change.
Background
The document responds to a color additive petition (3C0323) that sought to repeal regulations ensuring the safe use of FD&C Red No. 3. Micro‑Tracers, Inc., represented by Buchanan Ingersoll & Rooney PC, filed objections and asked for a public hearing after the original order granting the petition. The FDA had previously placed an administrative stay on the repeal, pausing its effect pending review of the objections. The agency’s review concluded the objections lacked material factual issues, prompting the lift of the stay. This action completes the agency’s procedural steps following the original petition.
Arguments For
Proponents argue that the existing regulations are unnecessary because FD&C Red No. 3 has been deemed safe under current scientific assessments, allowing industry to operate without redundant compliance burdens. Removing the specific safety provisions streamlines the regulatory framework and reduces administrative costs for manufacturers.
Arguments Against
The abstract indicates no substantial controversy; the agency found no material factual disputes, suggesting opposition was limited or unsubstantiated. No specific costs or safety concerns were raised in the filing.
Economic Considerations
Because the FDA did not provide an official cost‑benefit analysis, any economic effect must be inferred. Eliminating the specific safety regulations could lower compliance costs for manufacturers that currently must meet detailed testing or labeling requirements. Conversely, some stakeholders might incur costs if they choose to implement their own safety measures in the absence of the repealed rules. Overall, the impact is expected to be modest, but precise financial implications remain uncertain without a formal estimate.
Sections beyond the plain-English summary are AI-synthesized analysis based on the sourced Federal Register filing, read, edited where needed, and approved by a human editor before publication. Full methodology: Editorial & Methodology.
← All Records